Stuart K, Posner M, Campbell K, Huberman M
Department of Medicine, New England Deaconess Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Am J Clin Oncol. 1995 Aug;18(4):300-2. doi: 10.1097/00000421-199508000-00006.
Patients with metastatic colorectal carcinoma who have failed 5-fluorouracil-based chemotherapy have no effective second-line treatment available. Recent studies demonstrating clinical synergy between cisplatin and etoposide, and others exploring the efficacy of etoposide regimens utilizing chronic oral administration, suggested the utility of a new regimen incorporating these elements to treat refractory colorectal carcinoma. Fourteen patients were treated with weekly cisplatin and daily oral etoposide for 21 days in cycles of 28-35 days. Toxicity was significant, both hematologic and gastrointestinal in these pretreated patients. There were no objective responses, and median survival was 9.5 months. Weekly cisplatin and daily oral etoposide are poorly tolerated and ineffective in the treatment of refractory colorectal carcinoma. Further studies are needed to discover effective therapy for this disease.
接受过基于5-氟尿嘧啶化疗但失败的转移性结直肠癌患者没有有效的二线治疗方案。近期研究显示顺铂和依托泊苷之间存在临床协同作用，其他一些研究则探索了长期口服依托泊苷方案的疗效，这提示了一种包含这些成分的新方案用于治疗难治性结直肠癌的可行性。14例患者接受了每周一次的顺铂治疗以及每天口服依托泊苷，持续21天，每28 - 35天为一个周期。在这些经过预处理的患者中，血液学和胃肠道毒性均很显著。没有观察到客观缓解，中位生存期为9.5个月。每周一次的顺铂和每天口服依托泊苷耐受性差，对难治性结直肠癌治疗无效。需要进一步研究以发现针对这种疾病的有效治疗方法。
